biote Corp. (NASDAQ:BTMD) Shares Acquired by Barclays PLC

Barclays PLC grew its stake in biote Corp. (NASDAQ:BTMD) by 52.3% in the third quarter, Holdings Channel.com reports. The firm owned 77,196 shares of the company’s stock after acquiring an additional 26,510 shares during the quarter. Barclays PLC’s holdings in biote were worth $432,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in biote by 59.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock valued at $705,000 after buying an additional 34,999 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of biote in the second quarter valued at about $42,000. Rhumbline Advisers increased its position in biote by 104.2% during the second quarter. Rhumbline Advisers now owns 28,225 shares of the company’s stock worth $211,000 after purchasing an additional 14,404 shares during the last quarter. WINTON GROUP Ltd raised its stake in biote by 7.0% during the second quarter. WINTON GROUP Ltd now owns 47,725 shares of the company’s stock worth $357,000 after purchasing an additional 3,124 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after purchasing an additional 600,956 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

biote Price Performance

NASDAQ BTMD opened at $6.20 on Friday. biote Corp. has a 12 month low of $3.65 and a 12 month high of $8.44. The stock has a market capitalization of $336.89 million, a P/E ratio of 23.85 and a beta of 1.07. The firm’s 50-day moving average is $6.05 and its two-hundred day moving average is $6.31.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on shares of biote in a report on Monday, December 16th. They set a “buy” rating and a $12.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $9.11.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.